A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Trial Details

NCT ID
NCT05920356
Phase
PHASE3
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sotorasib
  • Pembrolizumab
Locations (sample)
  • Santa Barbara, California, United States|34.42083,-119.69819
  • Newark, Delaware, United States|39.68372,-75.74966
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Niles, Illinois, United States|42.01892,-87.80284
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and neg…
  • No history of systemic anticancer therapy in metastatic/non-curable settings
  • Eastern Cooperative Oncology Group (ECOG) ≤ 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →